Using a surveillance system to identify and treat newly acquired hepatitis C infection

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 12, 2008, Pages 1891-1894

  Walsh, Nick ^a,b,c   Lim, Megan ^a,b   Hellard, Margaret ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^c DANDENONG HOSPITAL   (Australia)

Author keywords

Hepatitis C virus (HCV); Injecting drug use (IDU); Intravenous; Population surveillance; Public health surveillance; Substance abuse

Indexed keywords

HEPATITIS C ANTIBODY; PEGINTERFERON;

ANTIVIRAL THERAPY; ARTICLE; AUSTRALIA; CLINICAL STUDY; DISEASE SURVEILLANCE; FEMALE; HEALTH SURVEY; HEPATITIS C; HUMAN; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; SEROLOGY;

EID: 57049089004     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05508.x     Document Type: Article

References (17)

1. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis c infection: a systematic review of longitudinal studies. J. Viral. Hepat. 2006 13 : 34 41.
2. NCHECR. HIV/AIDS, Viral Hepatitis and Sexually Transmissible Infections in Australia Annual Surveillance Report. Canberra, ACT : National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, NSW; Australian Institute of Health and Welfare, 2005
3. Robotin MC, Copland J, Tallis G et al. Surveillance for newly acquired hepatitis C in Australia. J. Gastroenterol. Hepatol. 2004 19 : 283 8.
4. Lauer GM, Walker BD. Hepatitis C virus infection. N. Engl. J. Med. 2001 345 : 41 52.
5. Pawlotsky JM. Therapy of hepatitis C: from empiricism to eradication. Hepatology 2006 43 : S207 20.
6. Jaeckel E, Cornberg M, Wedemeyer H et al. Treatment of acute hepatitis C with interferon alfa-2b. N. Engl. J. Med. 2001 345 : 1452 7.
7. Craxi A, Licata A. Acute hepatitis C: in search of the optimal approach to cure. Hepatology 2006 43 : 221 4.
8. Licata A, Di Bona D, Schepis F, Shahied L, Craxi A, Camma C. When and how to treat acute hepatitis C? J. Hepatol. 2003 39 : 1056 62.
9. Karakaltsas M. HIV, HCV, HTLV, and HBV Serology Screening Information Programme Report for the Diagnostic, Reference and Australian Red Cross Blood Service Laboratories. Melbourne : National Serological Reference Laboratory, 2006.
10. Wiegand J, Buggisch P, Boecher W et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 2006 43 : 250 6.
11. Broers B, Helbling B, Francois A et al. Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J. Hepatol. 2005 42 : 323 8.
12. Hahn JA, Page-Shafer K, Lum PJ et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J. Infect. Dis. 2002 186 : 1558 64.
13. Miller CL, Johnston C, Spittal PM et al. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002 36 : 737 42.
14. Maher L, Jalaludin B, Chant K, Kaldor J. Hepatitis C among intravenous drug users. Epidemiology 2005 16 : 423.
15. Chaves S, Widdowson MA, Bosman A. Surveillance of HCV infection in the Netherlands. Eur. Surveill. 2003 8 : 108 13.
16. Fleming DT, Zambrowski A, Fong F et al. Surveillance programs for chronic viral hepatitis in three health departments. Public Health Rep. 2006 121 : 23 35.
17. Meffre C, Larsen C, Perin A, Bouraoui L, Delarocque Astagneau E. Surveillance of screening for hepatitis C through the laboratory network RENA-VHC, France, 2000-2001. Eur. Surveill. 2003 8 : 101 7.